European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

Richard A.C. Hughes*, Pierre Bouche, David R. Cornblath, Eileen Evers, Robert D. Hadden, Isabel Illa, Carol L. Koski, Jean Marc Léger, Eduardo Nobile-Orazio, John D. Pollard, Claudia Sommer, Peter Van Den Bergh, Pieter A. Van Doorn, Ivo N. Van Schaik

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

69 Cites (Scopus)

Resum

Background: Several diagnostic criteria for multifocal motor neuropathy (MMN) have been proposed in recent years, and a beneficial effect of intravenous immunoglobulin (IVIg) and various other immunomodulatory drugs has been suggested in several trials and uncontrolled studies. Objectives: The aim of this guideline was to prepare consensus guidelines on the definition, investigation, and treatment of MMN. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library in July 2004 and prepared statements that were agreed in an iterative fashion. Recommendations: The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for MMN and investigations to be considered. The principal recommendations and good practice points were as follows: (1) IVIg (2 g/kg given over 2-5 days) should be considered as the first line of treatment (level A recommendation) when disability is sufficiently severe to warrant treatment; (2) corticosteroids are not recommended (good practice point); (3) if initial treatment with IVIg is effective, repeated IVIg treatment should be considered (level C recommendation). The frequency of IVIg maintenance therapy should be guided by the individual response (good practice point). Typical treatment regimens are 1 g/kg every 2-4 weeks or 2 g/kg every 4-8 weeks (good practice point); (4) if IVIg is not (or not sufficiently) effective, then immunosuppressive treatment may be considered. Cyclophosphamide, cyclosporine, azathioprine, interferon-β1a, or rituximab are possible agents (good practice point); and (5) toxicity makes cyclophosphamide a less desirable option (good practice point).

Idioma originalAnglès
Pàgines (de-a)1-8
Nombre de pàgines8
RevistaJournal of the Peripheral Nervous System
Volum11
Número1
DOIs
Estat de la publicacióPublicada - de març 2006

Fingerprint

Navegar pels temes de recerca de 'European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society'. Junts formen un fingerprint únic.

Com citar-ho